The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 Manufacturing . As is always the case with pharmaceuticals, the industry’s capabilities to manufacture and produce these potentially life-saving therapies will be of concern. .
52 
Let's personalize your content